Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRED-XT: Aspirin for Colorectal Cancer Risk Reduction
NCT05056896Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in colorectal cancer (CRC) comparing Placebo with Low Dose Aspirin (2 arms). Primary endpoint: Change of Intestinal Stem Cell Marker Gene Expression at 2 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05056896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056896.